Dendreon reports survival data on Provenge

02/14/2008 | Forbes

The overall survival of prostate cancer patients taking Dendreon's experimental vaccine Provenge appears to improve when they receive more potent doses of the drug, according to data the company released Thursday. Dendreon is trying to get FDA approval for the vaccine.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN